Suppression of Follicular Maturation by Infusion of a Luteinizing Hormone-Releasing Hormone Agonist Starting during the Late Luteal Phase in the Stumptailed Macaque Monkey

article OA: closed CC0 ⤵ 13 in-corpus citations
View on OpenAlex View on PubMed View at publisher
AI-generated summary by gemini-2.5-flash-lite, 2026-06-09

Continuous infusion of an LHRH agonist during the luteal phase of the macaque cycle suppressed estradiol secretion and inhibited ovulation, demonstrating a method for sustained medical oophorectomy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The effect of continuous administration of an LHRH agonist for 14 days on follicular estradiol secretion was studied in adult female stumptailed macaque monkeys. The infusion was started either during the early follicular phase or during the late luteal phase. Both treatments resulted in a rise in serum concentrations of LH and FSH for 2-3 days, after which time values returned to basal levels. Infusion during the early follicular phase induced a rapid rise in serum concentrations of estradiol, which declined after 7-10 days. The normal rise in serum progesterone after midcycle failed to occur, indicating that ovulation had been inhibited. Infusion during the late luteal phase of the cycle prevented the normal rise in serum concentrations of FSH and estradiol at the end of the luteal phase, and there was no indication of follicular estradiol production during the subsequent infusion period. Removal of the minipumps after 14 days was followed promptly by normal cycles, regardless of when the infusion had been started. In a second experiment, infusion of LHRH agonist was started during the luteal phase and extended for 90 days. This resulted in marked and sustained suppression of estradiol secretion and total absence of progesterone rises. These findings show that in the monkey, a rapid and sustained suppression of estradiol production can be obtained if a long term infusion of LHRH agonist is started during the luteal phase of the cycle. Such an approach in women using infusion pumps or sustained delivery preparations may be the most effective way of achieving a medical ovariectomy for the treatment of endometriosis, leiomyomata, and other estrogen-dependent pathological conditions.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Luteal Phase Ovarian Follicle Animals Buserelin Estradiol Estradiol Female Follicle Stimulating Hormone Follicle Stimulating Hormone Infusions, Parenteral Infusions, Parenteral Injections, Subcutaneous Injections, Subcutaneous Luteal Phase Luteinizing Hormone Luteinizing Hormone Macaca Ovarian Follicle Progesterone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (21)

Cited by (12)

Source provenance

europepmc
last seen: 2026-08-30T09:23:35.175841+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:45.632124+00:00
unpaywall
last seen: 2026-08-30T06:25:36.955031+00:00
License: CC0 · commercial use OK